Winrevair safety in Group 2/3 PH similar to Group 1 PAH
The risk for mortality and gastrointestinal/serious hemorrhage among Winrevair recipients did not differ between those with Group 2/3 pulmonary hypertension and those with pulmonary arterial hypertension, according to study results.
These real-world findings were presented as a poster at the European Respiratory Society International Congress.
“For the practicing clinician, these findings provide valuable real-world evidence regarding how sotatercept is being incorporated into routine pulmonary hypertension (PH) management,” Parth M. Rali, MD, FCCP, director of the Temple University Health